ResearcherMercer UniversityNo recent work listed

Fengbiao Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1953-5083; OpenAlex author ID A5006012268. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper

Papers 2

HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation. Co-author DOI 10.1186/s12935-020-01248-1 ↗
Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.cca.2018.11.023 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shi‐Wen Jiang · 2 shared papers, 2019–2020 · strength 0.26
- Paper HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation. DOI 10.1186/s12935-020-01248-1 ↗
- Paper Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. DOI 10.1016/j.cca.2018.11.023 ↗
Jinping Li · 2 shared papers, 2019–2020 · strength 0.26
- Paper HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation. DOI 10.1186/s12935-020-01248-1 ↗
- Paper Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. DOI 10.1016/j.cca.2018.11.023 ↗
Eseosaserea Igbinigie · 1 shared paper, 2019 · strength 0.12
- Paper Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. DOI 10.1016/j.cca.2018.11.023 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.